Skip to main content

Table 2 Summary of sensitivity analysis

From: Neuromuscular blocking agents for acute respiratory distress syndrome: an updated meta-analysis of randomized controlled trials

Outcome

Number of trials (patients)

Number of events in each group (%)

Statistical method

Pooled effect estimates

21~28d mortality [9, 16,17,18,19,20]

6 (1557)

Intervention: 253/785 (32.2%)

Control: 287/772 (37.2%)

M-H, Fixed, RR

0.87 (95% CI, 0.76 to 1.00); P = 0.05; I2 = 53%

28d mortality [9, 16,17,18,19]

5 (1461)

Intervention: 244/737 (33.1%)

Control: 269/724 (37.2%)

M-H, Random, RR

0.78 (95% CI, 0.58 to 1.06); P = 0.11; I2 = 50%

28d mortality [9, 16,17,18,19]

5 (1461)

Intervention: 244/737 (33.1%)

Control: 269/724 (37.2%)

M-H, Fixed, RR

0.90 (95% CI, 0.78 to 1.03); P = 0.12; I2 = 50%

ICU mortality [9, 16,17,18,19]

5 (1461)

Intervention: 259/737 (35.1%)

Control: 283/724 (39.1%)

M-H, Random, RR

0.82 (95% CI, 0.65 to 1.04); P = 0.11; I2 = 43%

90d mortality [9, 16,17,18,19]

5 (1461)

Intervention: 293/737 (39.8%)

Control: 315/724 (43.5%)

M-H, Random, RR

0.83 (95% CI, 0.65 to 1.06); P = 0.14; I2 = 49%

PaO2/FIO2 at 48 ha [16,17,18,19,20]

5 (1170)

NA

IV, Random, WMD

17.71 (95% CI, − 0.74 to 36.15); P = 0.06; I2 = 67%

PaO2/FIO2 at 48 hb [16,17,18,19,20]

5 (1170)

NA

IV, Random, WMD

26.98 (95% CI, 7.60 to 46.36); P = 0.006; I2 = 69%

PaO2/FIO2 at 48 hc [16,17,18,19,20]

5 (1218)

NA

IV, Random, WMD

19.69 (95% CI, 3.61 to 35.78); P = 0.02; I2 = 70%

PaO2/FIO2 at 72 h [9, 16,17,18]

4 (1437)

NA

IV, Random, WMD

14.59 (95% CI, 2.40 to 26.78); P = 0.02; I2 = 37%

Pplat at 48 h [16,17,18,19]

4 (1122)

NA

IV, Random, WMD

−0.08 (95% CI, − 0.76 to 0.59); P = 0.81; I2 = 0%

Pplat at 72 h [9, 16,17,18]

4 (1437)

NA

IV, Random, WMD

−0.70 (95% CI, − 1.48 to 0.09); P = 0.08; I2 = 25%

PEEP at 48 h [16,17,18,19]

4 (1122)

NA

IV, Random, WMD

−0.39 (95% CI, − 0.87 to 0.09); P = 0.11; I2 = 0%

PEEP at 72 h [9, 16,17,18]

4 (1437)

NA

IV, Random, WMD

−0.43 (95% CI, − 0.83 to 0.03); P = 0.03; I2 = 0%

DFV at day 28 [9, 16,17,18,19]

5 (1461)

NA

IV, Random, WMD

0.70 (95% CI, − 0.51 to 1.92); P = 0.26; I2 = 13%

Days not in ICU at day 28 [9, 16, 19]

3 (1369)

NA

IV, Random, WMD

0.18 (95% CI, − 0.96 to 1.31); P = 0.76; I2 = 13%

Barotrauma [9, 16,17,18,19]

5 (1461)

Intervention: 29/737 (3.9%)

Control: 52/724 (7.2%)

M-H, Random, RR

0.55 (95% CI, 0.35 to 0.85); P = 0.008; I2 = 0%

ICU-acquired weakness [9, 16,17,18]

4 (1437)

Intervention: 148/724 (20.4%)

Control: 118/713 (16.5%)

M-H, Random, RR

1.23 (95% CI, 0.99 to 1.53); P = 0.06; I2 = 0%

  1. M-H Mantel-Haenszel, RR Risk Ratio, IV Inverse Variance, WMD Weighted Mean Difference, d day, CI Confidence interval, FIO2 Action of inspiration O2, PaO2 Partial pressure of oxygen, Pplat Plateau pressure, PEEP Positive end-expiratory pressure, DFV Days free of ventilation, ICU Intensive care unit, NA Not available
  2. aIncluded moderate ARDS of Lyu only
  3. bIncluded severe ARDS of Lyu only
  4. cIncluded both moderate and severe ARDS of Lyu
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us